Insurance Dropped Your GLP-1? The Complete Appeal Playbook for CVS Caremark, Cigna, Aetna, UHC (2026)

Two specific 2026 events drive most of the “insurance dropped my GLP-1” queries: (1) the CVS Caremark July 2025 formulary swap that removed Zepbound from most commercial formularies in favor of Wegovy as the preferred step, and (2) the BMI clawback pattern — insurance covers your Wegovy or Zepbound for 6-12 months, you lose weight, your BMI falls below the coverage threshold, and reauthorization is denied at the next refill window. This playbook covers all four phases of recovery: (1) internal appeal with a Letter of Medical Necessity, (2) external review through the independent review organization, (3) cash-pay bridge while the appeal is in flight, (4) switch-brand strategies. Verbatim payer-policy quotes from Cigna and Aetna throughout.

Why insurance drops GLP-1 coverage in 2026

Five common scenarios surface in the 2026 patient-experience data:

1. CVS Caremark July 2025 Wegovy-preferred swap — CVS Caremark (Aetna's PBM, both CVS Health subsidiaries) removed Zepbound from MOST commercial formularies effective July 2025 in favor of Wegovy as the single preferred GLP-1 for weight loss. This formulary edit overrides bulletin 6947-C at point-of-sale on the affected formulary codes (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). A patient previously approved for Zepbound under bulletin 6947-C may receive a denial in 2026 even when they meet the same criteria. The fastest resolution is to switch to Wegovy under bulletin 4774-C.
2. BMI clawback at reauthorization — many plans only cover continued therapy when the patient maintains BMI above the original PA threshold (BMI ≥30, or ≥27 with comorbidity). Patients who lose enough weight to drop below the threshold are denied reauthorization at month 12 (Wegovy) or month 8 + 12 (Aetna 4774-C 7-month + 12-month sequence). Verbatim from Cigna IP0206 §III.1.B: “Approve for 1 year if … iii. Patient has lost ≥ 5% of baseline body weight; AND iv. The medication will be used concomitantly with behavioral modification and a reduced-calorie diet.” The 5% maintenance threshold is permissive — most patients who lost meaningfully will stay above it. The BMI threshold is the harder gate.
3. Step therapy not satisfied — Cigna CNF 360 verbatim p.3 (for Mounjaro, Trulicity, Victoza, Bydureon BCise): “If criteria for previous use of an oral medication for diabetes (not including Rybelsus or single-entity metformin) in the past 130 days are not met at the point of service … coverage will be determined by Prior Authorization criteria.” Patients who have only ever been on metformin for type 2 diabetes are denied Mounjaro at the pharmacy because metformin alone doesn't satisfy the step.
4. Documentation gap on reauthorization — the prescriber didn't submit the required attestation (e.g., the verbatim ≥5% weight-loss attestation; or the updated 6-month behavioral/dietary modification trial documentation per Aetna 4774-C). The PA system rejects and the pharmacy can't fill.
5. Plan changed obesity-medication policy — some employer plans removed all anti-obesity medications from the formulary entirely after the GLP-1 cost surge. Patients lose coverage at the next plan year transition even with a perfect clinical case.

Phase 1 — Internal appeal with Letter of Medical Necessity

Both Cigna and Aetna allow 180 days from the denial date to submit a written internal appeal on commercial plans (different deadlines apply to Medicare Part D / Medicare Advantage and to ERISA self-funded plans). Steps:

1. Request the written denial letter. The letter must specify which policy clause your submission failed to satisfy (per ACA 45 CFR §147.136 requirements). Example: “denied because patient does not have a documented 6-month comprehensive weight-management program per bulletin 4774-C.” That clause is your appeal target.
2. Get the actual policy document. Don't rely on the denial letter's paraphrase. Pull the verbatim PDF from the payer website (Cigna PDFs at static.cigna.com; Aetna PDFs at aetna.com/products/...) and read the specific clause your submission failed.
3. Have your prescriber draft a Letter of Medical Necessity (LOMN) that addresses the specific clause cited. Generic LOMN templates fail because they don't engage with the verbatim policy language. Use our GLP-1 PA letter generator which embeds the specific Cigna IP0206 / Aetna 4774-C / 6947-C clauses into the letter template.
4. File the internal appeal within the deadline (180 days commercial; 60 days Medicare). Include: the LOMN, the baseline + current BMI documentation, comorbidity documentation, prior medication trial history (especially if step therapy is the issue), the documented behavioral / dietary modification trial (3 months Cigna; 6 months Aetna), and (if reauth) the documented baseline weight-loss calculation. Submit via the payer's electronic appeal portal where available; track the case number.
5. Plan for the timeline. Standard internal appeals must be decided within 30 days for ongoing treatment denials and 60 days for completed-treatment denials per ACA. Expedited appeals (where delay would jeopardize health) must be decided within 72 hours.

Phase 2 — External review through the IRO

If the internal appeal is denied, you have the right to an external review by an independent review organization (IRO) under ACA. Key facts:

• You have 4 months from the final internal denial to request external review (some states have shorter windows; Cigna offers 2 levels of internal appeal in some plans).
• External review is binding on the plan. If the IRO overturns the denial, the plan must cover the drug.
• Expedited external review is available when delay would jeopardize health — must be decided within 72 hours.
• Standard external review typically takes 45 days from the request date.
• External review is free to the patient — payer pays for the IRO.
• Self-funded ERISA plans are not always subject to ACA external review — some are governed separately under ERISA federal regulations. Check your Summary Plan Description.
• External review is the right place to challenge a denial based on a medical-necessity disagreement (e.g., the plan says you don't have an “eligible comorbidity” but your prescriber documented one). External review is NOT for plan-design disputes (e.g., if the plan explicitly excludes all anti-obesity medications from the formulary, external review will uphold that exclusion).

Phase 3 — Cash-pay bridge while the appeal is in flight

Internal + external appeals can take 30-90 days during which you may not be able to get the medication. Cash-pay options verified live 2026-05-09:

For the full channel-by-channel guide with verbatim 2026 prices, see Wegovy GoodRx + Cash-Pay Coupon & Channel Guide . Brand and compounded GLP-1s are generally HSA/FSA eligible with a prescription per IRS Publication 502 — meaning you can pay from your HSA/FSA debit card during the appeal window.

Phase 4 — Switch-brand strategies

Sometimes the fastest resolution to a denial is not appealing — it's switching to a brand your formulary covers. The right switch depends on which brand your plan rejected:

• Denied Zepbound on a CVS Caremark formulary — switch to Wegovy. Bulletin 6981-A P04-2025 documents the formulary codes where Wegovy is the preferred step (ACCF/ACF/ACFC/SCCF/SF/SFC/VF/VFC). Wegovy under Aetna 4774-C / Cigna IP0206 will typically approve cleanly on the same patient. Note: tirzepatide produces greater mean weight loss than semaglutide per SURMOUNT-5 (NEJM 2025), so the switch may reduce your weight-loss trajectory — but covered Wegovy is better than denied Zepbound.
• Denied Wegovy at the BMI 27-29.9 threshold — review whether your prescriber documented one of Cigna's 11 listed comorbidities (per IP0206 §III.1.A verbatim): hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, polycystic ovarian syndrome, or coronary artery disease. PCOS, knee OA, and MASLD/NAFLD are commonly overlooked. Resubmit with one of these properly documented.
• Denied Mounjaro for type 2 diabetes — check whether the metformin step is satisfied. Verbatim from Cigna CNF 360 + Aetna 5468-C: a non-metformin, non-Rybelsus oral antidiabetic must be in the 130-day lookback. Single-entity metformin and Rybelsus do NOT satisfy the step. Add a sulfonylurea, DPP-4, SGLT2, or TZD trial to the chart and resubmit.
• Denied Mounjaro for off-label weight loss (no T2D diagnosis) — switch to Zepbound (the weight-management-indicated tirzepatide brand from the same manufacturer). Same molecule, same dose, same tolerability — different brand name + different policy gate.
• Denied Ozempic for off-label weight loss — switch to Wegovy (same molecule, weight-management indication).
• Denied any weight-management GLP-1 with no clear path — consider Foundayo (orforglipron oral GLP-1, FDA-approved April 2026, $149/month at LillyDirect / Amazon Pharmacy). New drug with the same FDA-approved weight-management indication; some plans haven't yet updated their PA criteria for it.
• Denied because plan excludes all anti-obesity medications — your only paths are (a) HR escalation requesting a benefit-design change at the next plan year, (b) a different plan at next open enrollment, or (c) cash-pay alternatives indefinitely. Appeals will uphold the explicit exclusion.

Medicare-specific path: the GLP-1 Bridge

Aetna and Cigna Medicare Advantage Part D members get a new coverage path effective July 1, 2026 through the CMS-mandated Medicare GLP-1 Bridge:

• Drugs included: Wegovy (all formulations), Zepbound KwikPen only (NOT vials or single-dose pens), Foundayo (all formulations).
• Drugs excluded: Saxenda is NOT in the bridge. Mounjaro/Ozempic/Rybelsus continue under their existing T2D Part D coverage.
• Eligibility: BMI ≥ 27 plus heart disease or prediabetes.
• Cost: $50/month flat copay.
• Caveats: the $50 copay does NOT count toward the deductible OR toward the $2,100 out-of-pocket cap. The bridge runs through December 31, 2027; coverage after that reverts to whatever Part D rules exist at that time.

Pre-bridge (before 07/01/2026), MA-PD weight-loss-only coverage is statutorily prohibited (Social Security Act §1860D-2(e)(2)(A)). Wegovy MACE indication and Zepbound OSA indication remain Part D-coverable on most MA-PD plans because the indication is non-weight-loss.

Pre-appeal documentation checklist

Before the LOMN goes out, confirm your chart has:

• Baseline BMI with measured (not patient- reported) height and weight at the start of therapy
• Current BMI with measured weight at the most recent encounter
• Comorbidity diagnosis — ICD-10 code(s) for each comorbidity that satisfies the BMI 27-29.9 pathway (Cigna's 11-condition list per IP0206 verbatim, or Aetna's comorbidity criteria per 4774-C)
• Prior medication trial history — every oral antidiabetic in the 130-day lookback for diabetes GLP-1s; every prior weight-loss drug or program for weight-management GLP-1s
• 3- or 6-month behavioral / dietary modification documentation — Cigna IP0206 requires 3 months; Aetna 4774-C requires 6 months. The chart needs to show behavioral modification + reduced-calorie diet + (per Aetna) increased physical activity. A single line in the assessment is usually enough; zero documentation is the common failure point.
• Reauthorization weight-loss attestation (if reauth) — Wegovy/Zepbound/Foundayo/Saxenda all require ≥5% baseline body-weight loss for continuation. Saxenda is the exception with a 4% threshold per Aetna 1227-C. Pediatric Wegovy is ≥1% BMI reduction.
• Concomitant lifestyle attestation — every GLP-1 PA requires the prescriber to attest that the drug is being used “concomitantly with behavioral modification and a reduced-calorie diet.”

Practical takeaways

• The CVS Caremark July 2025 swap is real and ongoing. If you were previously approved for Zepbound and got denied in 2025-2026 with no clinical change, this is almost always why. Switching to Wegovy is the fastest fix.
• Generic LOMN templates fail. Your prescriber needs to engage with the verbatim policy clause cited in the denial letter. The PA letter generator we ship embeds the actual Cigna/Aetna criteria into the letter — see GLP-1 PA letter generator .
• External review is binding on the plan and free to the patient. Most patients never use it because the internal appeal succeeds. But if the internal appeal is denied, request external review — IROs frequently overturn payer decisions when the medical-necessity case is strong.
• Cash-pay bridge options are cheaper than ever. NovoCare $299/month Wegovy + LillyDirect $299-$449/month Zepbound + $149/month Foundayo make out-of-pocket survivable for most patients during a 60-90 day appeal window. See our cash-pay coupon & channel guide .
• Medicare GLP-1 Bridge starts 07/01/2026. If you're an Aetna or Cigna MA-PD member with BMI ≥27 + heart disease / prediabetes, mark the date.
• If you switch from Zepbound to Wegovy (or vice versa) after a formulary edit, treat it as a full re-titration. Both drugs' FDA labels say to start at the lowest dose regardless of prior GLP-1 exposure (Wegovy 0.25 mg or Zepbound 2.5 mg) and follow the standard 4-week-per-step ladder. SURMOUNT-5 (PMID 40353578) — the only published head-to-head trial — found similar tolerability between the two but ~22% vs ~14% mean weight loss in favor of tirzepatide at 72 weeks. See our Wegovy ↔ Zepbound switch dose-equivalence guide for the verbatim §2 dose ladders, the SURMOUNT-5 findings, the re-titration logic in either direction, and the side-effect reset patients should expect on the new drug starting dose.

For the patient-facing flip-side — the full Wegovy alternatives map (higher-effect Zepbound, oral Foundayo, Saxenda + the Teva generic from August 2025, compounded semaglutide as a cash-pay option with regulatory caveats, and the non-GLP-1 oral alternatives) — see our Wegovy alternatives 2026 complete guide .

For Texas Medicaid members specifically — the second- largest US Medicaid population — the appeal pathway adds two state-specific escalation layers (Texas HHSC State Fair Hearing and Texas Department of Insurance IRO external review) and a non-Covered-Benefit determination floor that no appeal can fix for Wegovy or Saxenda. See our Texas Medicaid GLP-1 coverage + STAR+PLUS PA pathway (2026) for the verbatim Acentra Jan 30, 2026 PDL Criteria Guide quotes, the Superior HealthPlan “Non-Covered Benefit” coverage table, and the failed HB 2412 legislative context.

For California Medi-Cal members — the largest US Medicaid population — the appeal pathway runs through a State Hearing administered by the California Department of Social Services (CDSS) within 90 days of the Notice of Action, with a 10-day “aid paid pending” window for members already taking the GLP-1 on or before January 1, 2026. California reversed course on weight-management GLP-1 coverage effective January 1, 2026 (Wegovy, Zepbound, and Saxenda removed from the Medi-Cal Rx CDL); Wegovy was added back April 1, 2026 for noncirrhotic MASH only, with ICD-10-CM K76.0 / K75.8 required on the pharmacy claim. See our California Medi-Cal GLP-1 coverage (2026): the state reversal that removed Wegovy + Zepbound for weight loss for the verbatim Medi-Cal Rx alerts, the May 1, 2026 CDL diagnosis-restriction logic, and the State Hearing pathway.

For New York Medicaid (NYRx) members — the fourth- largest US Medicaid population at ~7M enrollees — the appeal pathway runs through a Fair Hearing administered by the New York State Office of Temporary and Disability Assistance (OTDA), within the time window stated on the Notice of Action (typically 60 days for Medicaid fair- hearing rights). The substantive coverage barrier is materially harder to overcome than in any other state in this 50-state series so far: New York's exclusion is triple-anchored by federal statute (42 USC § 1396r-8(d)(2)(A)), state regulation (18 NYCRR § 505.3(g)(3)), AND explicit drug-brand-named NYRx contractor documentation. A Fair Hearing cannot fix a policy-level determination, but it CAN reverse adjudication-error appeals (Wegovy MACE- pathway BMI / CVD-therapy / lifestyle documentation issues, the anti-stockpiling 25%-of-current-fill rule, Imcivree genetic-confirmation issues). NYRx covers Wegovy only via the stricter-than-FDA-label MACE pathway (BMI ≥ 40 plus established CVD plus 6 months of CVD-therapy adherence plus a lifetime cap of 2 attempts). See our New York Medicaid (NYRx) GLP-1 coverage and Wegovy MACE pathway (2026) for the verbatim NYRx PDL entries, the 11-question Wegovy PA Form, the anti-stockpiling rules, and the OTDA Fair Hearing pathway.

For Nevada Medicaid members — administered by the Nevada Health Authority (NVHA) with Magellan/Prime Therapeutics as the FFS PBM — the appeal pathway after a Wegovy denial runs through a Nevada Health Authority Fair Hearing (within 90 days) after exhausting the MCO internal appeal (within 60 days). Critical distinction: Wegovy IS covered in Nevada Medicaid for the FDA-approved MACE cardiovascular indication (age ≥ 18, BMI ≥ 27, established CVD, no T1DM/T2DM — Web Announcement 3337, April 22, 2024). A denial for a patient who meets all MACE criteria is likely an adjudication error, appealable through the MCO internal process before escalating to NVHA. Denials for pure chronic weight management have no operational PA pathway — the Pharmacy Manual § 3.7 categorical exclusion applies. SB 244 (the 2025 legislative mandate) died in committee June 3, 2025. See Nevada Medicaid GLP-1 coverage (2026): Pattern #31 for the full PA criteria, five-MCO service-area matrix, and SSSB non-action history.

For Florida Medicaid members — the third-largest US Medicaid population, with most recipients enrolled in the Statewide Medicaid Managed Care (SMMC 3.0) program — the appeal pathway runs through a Fair Hearing administered by the Florida Department of Children and Families (DCF) / Office of Medicaid Hearings and Compliance (OMC), typically within 90 days of the Notice of Action. The structural appeal framework requires the same adjudication-error vs policy-level distinction that applies in every state. A Fair Hearing CAN reverse adjudication-error denials (HbA1c documentation missing or misapplied, metformin contraindication not evaluated, Trulicity minimum-age-10 criterion applied incorrectly for adolescent patients, non-preferred step-therapy documentation not reviewed). A Fair Hearing CANNOT fix a policy-level determination: Florida's exclusion of Wegovy, Zepbound, and Saxenda for the weight-management indication is established by the operational silence of the AHCA PDL — no appeal can add a drug to the PDL. Unlike Texas (which has an explicit “Non-Covered Benefit” label) or New York (which has a triple-anchored explicit regulatory exclusion), Florida's exclusion is proven by absence rather than by a single AHCA bulletin — but the practical effect on appeal outcomes is identical: a Fair Hearing cannot override PDL-based non-coverage. See our Florida Medicaid GLP-1 coverage (2026): the silent exclusion for the verbatim AHCA PDL entries, the five-criterion T2D PA checklist, the five SMMC plan-level deferral statements, and the DCF / OMC Fair Hearing pathway with adjudication-error vs policy-level distinction.

For Ohio Medicaid members — served through the Gainwell Technologies Single Pharmacy Benefit Manager (SPBM), which administers the Unified Preferred Drug List (UPDL) for all managed-care plans and fee-for-service members statewide — the appeal pathway runs through a State Hearing under Ohio Administrative Code Rule 5101:6-3-02 , with a filing window of 90 calendar days from the mail date of the adverse notice (or 90 days from the MCP appeal resolution for managed-care members). The Ohio framework requires the same critical adjudication-error vs policy-level distinction that applies in every state — but Ohio makes the distinction starker than any other state in our series. Ohio Administrative Code Rule 5160-9-03(D) explicitly states that drugs on the non-covered list “are not eligible for prior authorization” — meaning a Wegovy, Zepbound, or Saxenda denial for the weight-loss indication is a coverage exclusion, not a PA adjudication. A State Hearing officer cannot override an OAC rule; a policy-level weight-loss appeal will not succeed. Where a State Hearing CAN be effective: Wegovy MACE-pathway denials (January 7, 2026 Metabolic Modifiers class, BMI ≥ 27, no T1D/T2D, documented prior MI/stroke/symptomatic PAD) where documentation was present but misapplied — A1C misread, CVD event not recognized, or concurrent CVD-medication contraindication not evaluated; and Wegovy MASH-pathway denials (noncirrhotic F2/F3 fibrosis) where biopsy or dual-imaging-biomarker documentation was submitted but not reviewed correctly at the 180-day renewal. See our Ohio Medicaid GLP-1 coverage (2026): triple-anchored exclusion + January 2026 Wegovy MACE/MASH carve-back-in for the verbatim OAC citations, the SPBM Nov 7, 2025 claim-gate notice, the Metabolic Modifiers PA criteria, and the OAC 5101:6-3-02 State Hearing pathway with the adjudication-error vs policy-level distinction.

Pennsylvania Medicaid is the prime policy-reversal case study in this playbook — the only state in our series where patients were actively receiving GLP-1s under a covered obesity pathway and then lost that coverage due to a deliberate state policy change, not a commercial formulary swap. Pennsylvania covered GLP-1 receptor agonists for chronic weight management at full FDA-label thresholds (BMI ≥ 30; BMI ≥ 27 with comorbidity) from January 2023 through December 31, 2025. Medical Assistance Bulletin MAB2025112403 (effective January 1, 2026) terminated that pathway for approximately 70,000 beneficiaries and simultaneously invalidated all existing GLP-1 PAs regardless of indication. The PA appeal pathway runs through the Bureau of Hearings and Appeals (BHA) under 55 Pa. Code § 275.4: file within 15 days of the denial notice to preserve “aid pending appeal” (continued coverage while appeal is pending); file within 30 days to preserve appeal rights at all. For HealthChoices MCO denials, the MCO internal grievance must be exhausted first. A BHA fair hearing cannot override a policy-level coverage determination — a weight-management denial under MAB2025112403 will not succeed — but EPSDT-based arguments for patients under 21 are the strongest exception path. PA's non-obesity carve-outs (Wegovy MACE at BMI ≥ 27 with no T2D exclusion — the most patient-favorable MACE pathway in the cluster; Wegovy MASH with ELF score and age-stratified FIB-4; Zepbound OSA) mean that patients with established CVD, MASH, or severe OSA may have a viable PA pathway even post-termination. See our Pennsylvania Medicaid GLP-1 coverage 2026: the policy reversal for the verbatim MAB2025112403 PA criteria, the triple-anchor termination documentation, the 34-month coverage history, and the BHA appeal timeline with the 15-day aid-pending-appeal window.

New Hampshire Medicaid (Pattern #25) is the third state in the KFF January 2026 four-state elimination cluster (CA + NH + PA + SC) and the state with the leanest termination authority in the 25-state series — a single one-page DHHS Provider Notification dated October 9, 2025 with no NH RSA, no He-W rule amendment, and no DUR Board action. NH preserved four non-obesity indications (T2DM, MACE, OSA, MASH) but published no indication-specific PA criteria documents for MACE, OSA, or MASH. The NH appeal pathway is anchored in NH He-W 570.06 with a 30-calendar-day appeal window from the written denial notice. For FFS members, file with the NH DHHS Administrative Appeals Unit at (603) 223-4774 or (866) 291-1674. For MCO members (AmeriHealth Caritas NH, NH Healthy Families, WellSense NH), exhaust the MCO internal appeal first, then request a DHHS fair hearing. A fair hearing can reverse adjudication-error denials for the MACE, OSA, or MASH carve-out indications where documentation was present but incorrectly evaluated. A fair hearing cannot override the policy-level weight-loss termination. The strongest exception pathway is EPSDT medical necessity for members under 21. SB 455 — the 2026 legislative restoration vehicle — was blocked 13–2 at the House Commerce Committee; as of May 10, 2026, no NH legislation restoring obesity-indication coverage has advanced. See our New Hampshire Medicaid GLP-1 coverage (2026): Pattern #25 for the verbatim DHHS notification, the four preserved indications, the NH.PMN.50 MCO policy, the SB 455 legislative record, and the He-W 570.06 appeal timeline.

South Carolina Medicaid (Healthy Connections, Pattern #26) closes the KFF January 2026 four-state elimination cluster (CA + NH + PA + SC) as the state with the shortest coverage window (14 months, November 2024 – December 2025) and the lowest documentary footprint — termination anchored in a 4-sentence P&T Committee minutes State Update paragraph, not a published Medical Assistance Bulletin or regulatory amendment. Preserved non-obesity indications: Wegovy for MACE/MASH (per P&T minutes prose, no published PA criteria document). The SC fair hearing pathway runs through the SCDHHS Office of Appeals and Hearings with a 30-calendar-day appeal window from the notice of action; hearing officer decisions within 90 days; further appeal to the SC Administrative Law Court (ALC, (803) 734-0550) with a $25 filing fee (waivable for indigency). The critical SC-specific YMYL risk: Healthy Blue's formulary lists Wegovy subcutaneous as “Covered” in an “ANTI-OBESITY - GLP-1 RECEPTOR AGONISTS” class — this reflects MACE/MASH non-obesity indications only; the categorical sPDL exclusion overrides the formulary entry for weight management. Contact Disability Rights South Carolina (disabilityrightssc.org) for free fair hearing representation. See our South Carolina Medicaid GLP-1 coverage 2026: Pattern #26 for the verbatim P&T minutes paragraph, the Pharmacy Services Provider Manual categorical exclusion, the Absolute Total Care MCO three-date timeline, the Healthy Blue formulary trap analysis, and the full SCDHHS appeal pathway.

Colorado (Health First Colorado / Pattern #27): Health First Colorado members denied Wegovy or Zepbound for the weight-loss indication have a state fair hearing pathway through the Colorado Office of Administrative Courts (OAC) — phone (303) 866-5626, 1525 Sherman St., 4th Floor, Denver, CO 80203. Filing deadline: 60 days from the Notice of Action. If filed within 10 days and services are currently active, continuation of benefits may be requested pending the hearing. An Administrative Law Judge hears the case and issues an Initial Decision; the HCPF Office of Appeals (303) 866-5654 reviews for final determination. Appeals for weight-loss-only denials will be sustained (10 CCR 2505-10 § 8.800.4.B.2.a is binding); the strongest appeal posture is when CVD (for the Wegovy CV pathway, BMI ≥ 25) was not properly evaluated in the initial PA review. See our Colorado Medicaid GLP-1 coverage 2026: Pattern #27 for the verbatim PDL carve-out criteria, the MedImpact pharmacy PA process (888-672-7203), the SB 25-048 commercial mandate analysis, and the full OAC fair hearing pathway.

Iowa Medicaid (Iowa Health Link / Pattern #32): Iowa Medicaid GLP-1 PA denials are adjudicated centrally by the state Optum-administered PA queue, not by the MCOs (Iowa Total Care, Wellpoint Iowa, Molina). For pharmacy/FFS PA denials — which is what Wegovy and Zepbound carve-out denials are — file a state fair hearing request with Iowa HHS Appeals within 90 calendar days of the written denial notice (the 120-day MCO window does NOT apply to centrally-adjudicated pharmacy PA denials). The file is forwarded to the Department of Inspections, Appeals and Licensing (DIAL) Administrative Hearings Division (dial.iowa.gov/hearings/admin-hearings), which schedules a telephone hearing before an independent administrative law judge. Critical framing: a chronic-weight-management denial CANNOT be overturned on appeal — IAC 441-78.2(4)(b)(2) is a binding regulatory exclusion. The strongest Iowa appeal posture is for MACE/OSA/MASH patients who had a documentation deficiency (missing CVD diagnosis code, AHI value not documented on form, FibroScan result not attached) that could be corrected on resubmission. Provider Help Desk: 1-877-776-1567. PA fax: 1-800-574-2515 (form 470-0058). See our Iowa Medicaid GLP-1 coverage 2026: Pattern #32 for the full DIAL fair hearing pathway, unified PA form 470-0058 criteria, and Iowa’s PDL comment code 12 dual-signaling pattern.

Connecticut Medicaid HUSKY Health (Pattern #30): Connecticut is FFS-only (no MCOs since 2012), so HUSKY pharmacy PA denials skip the MCO internal-appeal step and go directly to the DSS Office of Legal Counsel, Regulations and Administrative Hearings (OLCRAH) at 55 Farmington Avenue, Hartford, CT 06105. File within 60 days of the Notice of Action date (not receipt date); for HUSKY Medicaid (A/C/D), request continuation of benefits by filing before the proposed action date. Hearing decision within 90 days; reconsideration within 15 days. Free legal aid: Statewide Legal Services 1-800-453-3320. PA fax (Gainwell): 1-866-759-4110. The strongest appeal posture: documentation-deficiency cases (missing diagnosis code, incomplete PA form, wrong ICD-10 field) that were correctable. A hearing cannot override the categorical exclusion for chronic weight management — if you do not meet MACE/MASH/OSA criteria, the exclusion stands. LMN pathway available: rx.lmn@ct.gov. Note that HUSKY B (CHIP) members are excluded from the Wegovy MASH carve-out (PB 2025-54, HUSKY A/C/D only) — a HUSKY B denial on Wegovy for MASH cannot be appealed on coverage grounds. See our Connecticut Medicaid HUSKY Health GLP-1 coverage 2026: Pattern #30 for the verbatim DSS PA criteria, the triple-vendor PBM contact table (Gainwell / Prime / Acentra), and the full OLCRAH fair hearing pathway.

Louisiana Medicaid (Healthy Louisiana / Pattern #28): Louisiana Medicaid members denied a Wegovy CV or Zepbound OSA PA have a three-stage appeal pathway: (1) internal MCO appeal within 60 calendar days of the Notice of Action; MCO written decision within 30 calendar days; if filed within 10 days, current services continue during review; (2) State Fair Hearing before the Louisiana Division of Administrative Law (DAL) within 120 days of the MCO appeal decision — you must complete the MCO appeal first; (3) DAL ALJ hearing on the merits. MCO PA phone lines: Aetna Better Health 1-855-242-0802; AmeriHealth Caritas 1-800-684-5502; Healthy Blue 1-844-521-6942; Humana 1-800-555-2546; Louisiana Healthcare Connections 1-866-595-8133; FFS (ULM/Gainwell) 1-866-730-4357. The strongest appeal posture: documentation deficiencies (missing Patient Treatment Agreement, missing ABI measurement, missing PSG sleep study) that were correctable. A fair hearing cannot override the categorical exclusion — if a member does not meet the CV or OSA criteria, the exclusion stands. See our Louisiana Medicaid GLP-1 coverage 2026: Pattern #28 for the verbatim LDH PA criteria, the 5-MCO PBM identity table, the Patient Treatment Agreement requirements, and the full DAL fair hearing pathway.

Oregon Medicaid (Oregon Health Plan / Pattern #29): Oregon Health Plan members denied a Wegovy CV, Wegovy/Liraglutide MASH, or Zepbound OSA PA have a two-tier appeal pathway. Tier 1: CCO-level appeal filed within 60 calendar days of the Notice of Adverse Benefit Determination; CCO written decision within 16 calendar days (with optional 14-day extension); continuation of benefits is available during appeal if the service is ongoing. Tier 2: OHA Administrative Hearing filed within 120 days of the CCO Notice of Appeal Resolution — before an Administrative Law Judge (ALJ) at the Oregon Office of Administrative Hearings. OHA Medical Hearings Unit: 503-945-5785; OHAMedical.Hearings@odhsoha.oregon.gov; FFS (not in a CCO): 1-800-273-0557. The strongest appeal posture is documenting that the PA reviewer failed to evaluate a qualifying Table 3 indication (CV, MASH, or OSA) — not arguing that Guideline Note 5’s categorical weight-loss exclusion should be overridden, which an ALJ will sustain. A categorical denial on weight-loss-only grounds is binding under OAR 410-121-0040 and HERC Guideline Note 5. See our Oregon Medicaid GLP-1 coverage 2026: Pattern #29 for the verbatim Weight Management Drugs PA criteria, the CareOregon and Trillium CCO criteria, the Guideline Note 5 exclusion mechanism, and the full OHA administrative hearing pathway.

Arkansas Medicaid (Pattern #34): Arkansas Medicaid FFS and PASSE members denied a Wegovy CV, Zepbound OSA, or Wegovy MASH PA must file a written appeal with the AR DHS Office of Appeals and Hearings within 30 days of the denial date. Mail to: Department of Human Services, Office of Appeals and Hearings, P.O. Box 1437, Slot S101, Little Rock, AR 72203-1437. Hearings are conducted by telephone unless either party requests in-person. The hearing officer is appointed by DHS; the final agency decision is binding subject to further appeal to Arkansas state courts. A chronic-weight-management denial will be upheld — the categorical exclusion is anchored at four independent authority levels plus ACT 628 § 20-77-154(c) (effective January 1, 2026), which explicitly bars coverage of “injectable drugs to lower glucose levels or any other drugs prescribed for weight loss.” Appeals succeed when: (1) the patient has a qualifying FDA-label indication (CVD / OSA / MASH) but the PA was denied for a documentation deficiency; (2) the denial letter cited incorrect criteria; or (3) the prescriber can supply missing documentation (PSG report, FibroScan result, cardiology note, CPAP usage report). ARHOME members: appeal through your QHP carrier first, then escalate to the AR Insurance Department or DHS Office of Appeals and Hearings. See our Arkansas Medicaid GLP-1 coverage 2026: Pattern #34 for the verbatim DUR Board PA criteria across all three carve-outs, the three-way program bifurcation (FFS/PASSE/ARHOME), ACT 628 full statutory text, and the Prime Therapeutics contact table.

New Mexico Medicaid — Turquoise Care (Pattern #33): New Mexico Medicaid members denied any Wegovy, Zepbound, Saxenda, or Imcivree PA face the strongest categorical-exclusion posture in the Mountain West cluster. The exclusion is anchored at five levels (federal optional exclusion at 42 U.S.C. § 1396r-8(d)(2)(A), state regulation NMAC 8.324.4.14(A)(8) — “weight loss/weight control drugs,” the HCA Weight Reduction Medications page two-column “Not Covered” list, the BCBSNM Blue Cross Community Centennial Drug List, and the UHC NM Medicaid PDL categorical “Anti-obesity agents” exclusion) — a chronic-weight-management denial WILL be upheld on appeal. Filing track for FFS members or after MCO appeal exhaustion: request a State Fair Hearing from the HCA Office of Administrative Continuations (OAC) within 90 days of the adverse action under NMSA 27-3-3, which states verbatim: “An applicant for or recipient of public assistance who is aggrieved because of the department's decision … shall have the right to a fair hearing.” MCO-member track: file an internal appeal first (30 calendar days standard, 72 hours expedited) with your MCO (BCBSNM, Molina, Presbyterian, or UHC Community Plan) before escalating to OAC. Appeals are most likely to succeed when arguing legacy-AOM PA documentation completeness (Didres, Fastin, Sanorex, Tenuate, Xenical) under the BMI > 40 or BMI > 35-with-comorbidity pathway, NOT when contesting the modern-GLP-1 categorical exclusion. See our New Mexico Medicaid GLP-1 coverage 2026: Pattern #33 for the verbatim NMAC 8.324.4.14(A)(8) text, the HCA Weight Reduction Medications page exclusion list, the four-MCO PBM architecture (Prime Therapeutics, Capital Rx, CVS Caremark, OptumRx), SB 193 (2025) legislative history, and the KFF “covering” YMYL trap (KFF's classification reflects legacy AOMs only, not Wegovy/Zepbound/Saxenda).

Mississippi Medicaid — Division of Medicaid (Pattern #35): Mississippi is the only non-expansion southern state with affirmative chronic-weight-management Medicaid GLP-1 coverage — meaning the appeal posture is fundamentally different from non-coverage southern peers. Wegovy and Saxenda ARE covered as Preferred Antiobesity Select Agents for ages 12 and older under SPA 23-0013 (effective July 1, 2023) and the DOM Anti-obesity Select Agents PA Criteria Version 10 (effective April 1, 2026). Denials are therefore typically documentation-deficiency denials rather than categorical denials, and the appeal posture should focus on documenting the qualifying BMI + comorbidity profile + 12-month treatment plan attestation + dietary/physical-activity counseling. File the appeal through the DOM Medicaid Appeals SharePoint portal under 23 Miss. Admin. Code Part 300 Chapter 3 Rule 3.1 — access is granted on request by emailing Medicaid.Appeals@medicaid.ms.gov. The standard federal-state Medicaid appeals framework applies under 42 C.F.R. § 431 Subpart E. Practical denial-recovery path: (1) internal reconsideration at Gainwell (call 1-833-660-2402 before escalating); (2) written appeal via the Medicaid.Appeals portal; (3) fair hearing; (4) final administrative decision; (5) judicial review under the Mississippi Administrative Procedures Law (Miss. Code Ann. §§ 25-43-3.115 et seq.). For Zepbound requests specifically, the appeal posture is weaker — Zepbound is NOT enumerated on the Universal PDL and no Zepbound PA Criteria document exists, so the drug is presumptively non-covered under Miss. Admin. Code Title 23 Part 214 Rule 1.3.B.1. An appeal requesting Zepbound coverage cannot succeed absent a DOM policy change. For Contrave and Qsymia denials, the verbatim DOM rationale “This agent is not rebated through CMS” anchors the non-coverage decision to a federal-statutory fact (manufacturer rebate participation) and cannot be overturned at the state appeal level. See our Mississippi Medicaid GLP-1 coverage 2026: Pattern #35 for the verbatim SPA 23-0013 carve-back-in mechanism, the Antiobesity Select Agents PA Criteria Version 10 (Wegovy + Saxenda), the Wegovy in MASH PA Criteria Version 1 (Oct 30, 2025), the Gainwell Technologies single-PBA architecture, and the MississippiCAN CCO (Magnolia/Molina/TrueCare) cross-references.

West Virginia Medicaid — Bureau for Medical Services (Pattern #36): West Virginia Medicaid does NOT cover GLP-1s for chronic weight management. Both BMS Office of Pharmacy Services PA criteria documents state verbatim: “Agents used for the purpose of weight loss are typically a benefit exclusion.” The Zepbound document is more emphatic: “Agents used for the purpose of weight loss are typically a benefit exclusion and not covered by West Virginia Medicaid.” A chronic-weight-management-only denial will be upheld on appeal — the exclusion is anchored to 42 U.S.C. § 1396r-8(d)(2)(A) and the explicit BMS criteria language. Three FDA-label carve-outs are available via WVU Rational Drug Therapy Program (RDTP) at the WVU School of Pharmacy (PA review): (1) Wegovy CV (eff. Jan 1, 2026 — BMI ≥ 27, established CVD, HbA1c ≤ 6.5% excludes T2D, cardiology/vascular/neurology consult, 90-day initial); (2) Wegovy MASH (same PA document — F2–F3 fibrosis biopsy OR FibroScan/MRE, GI/hepatology consult, 90-day initial / 1-year reauth); (3) Zepbound OSA (eff. Jul 1, 2025 — AHI ≥ 15, BMI ≥ 30, CPAP counseling, T2D patients first fail preferred T2D GLP-1 compliantly for 3 months, 150-day initial). Appeal filing track: WV DHS Board of Review under WV Code § 9-2-9, within 90 days of the adverse-action notice; hearing before an administrative law judge; final agency decision; judicial review in WV circuit court. RDTP: 1-800-847-3859 / fax 1-800-531-7787. Gainwell Technologies (PBM): 1-888-483-0801 (provider) / 1-888-483-0797 (member). BMS Office of Pharmacy Services: 304-558-1700. Appeals are strongest when documenting the FDA-label criteria gates (ABI ≤ 0.85 for PAD, NAFLD activity score ≥ 4 with steatosis/ballooning/lobular inflammation > 1 for MASH, AHI ≥ 15 for OSA) that were missing from the original PA submission — not contesting the categorical exclusion. See our West Virginia Medicaid GLP-1 coverage 2026: Pattern #36 for the verbatim Wegovy CV + MASH and Zepbound OSA PA criteria, the WVU RDTP architecture, the HbA1c ≤ 6.5% diabetic-exclusion gate, the T2D step-therapy bridge on Zepbound OSA, and the full BMS Board of Review filing procedure.

Utah Medicaid — Department of Health and Human Services (Pattern #37): Utah Medicaid uniquely covers chronic-weight-management Saxenda, Wegovy, and Zepbound (adults 18+ and pediatric ages 12–17 with BMI ≥ 95th percentile, Wegovy + Saxenda only) UNDER A LEGISLATIVE PILOT PROGRAM — with explicit verbatim PA form sunset language: “Coverage for weight-loss is part of a pilot program and may not continue past 6/30/2026.” Three indication-permanent carve-outs continue post-sunset: Wegovy MACE (6/12-mo PA, established CVD + concurrent guideline-recommended secondary prevention), Zepbound OSA (12/12-mo PA, strictest OSA in series: in-lab attended PSG + 70% PAP adherence required), Wegovy MASH (6/12-mo PA, dual-modality FIB-4 + biopsy/VCTE/ELF/MRE). Appeal filing track: Utah DHHS Medicaid administrative hearing process under 42 C.F.R. § 431 Subpart E; contact Pharmacy PA Team at 855-828-4992 first to verify denial rationale; re-submit with additional documentation (current weight/height/BMI, all six universal criteria attestations, indication-specific evidence); if denial stands, request fair hearing through Utah DHHS Medicaid; hearing before an administrative law judge; final agency decision; judicial review in Utah district court. For chronic-weight-management denials in the months leading up to and following June 30, 2026, the appeal posture depends entirely on Utah Legislature action on the pilot — if the pilot does NOT renew, post-sunset weight-loss denials cannot be overturned at the agency level (denial would be anchored to absent legislative authority). Patients should plan ahead: monitor Utah Medicaid pharmacy bulletins through May–June 2026 for renewal announcements; discuss transition to an indication-permanent pathway with prescriber if clinically appropriate (Wegovy MACE if established CVD; Wegovy MASH if F2–F3 confirmed; Zepbound OSA if AHI ≥ 15 in-lab PSG); prepare for potential cash-pay coverage starting July 1, 2026 if pilot does not renew. See our Utah Medicaid GLP-1 coverage 2026: Pattern #37 for the verbatim pilot-program sunset language, the unified 11-part PA form covering all six indications, the indication-permanent carve-outs, and the full transition-planning playbook for the June 30, 2026 sunset.

Further reading

• Top GLP-1 insurance-coverage questions on Reddit, answered
• GLP-1 contraindications cheat sheet